Diagnostic work up to assess early response indicators in invasive pulmonary aspergillosis in adult patients with haematologic malignancies
Corresponding Author
Werner J. Heinz
Klinikum Weiden, Weiden, Würzburg university medical center, Würzburg, Germany
Correspondence
Werner J. Heinz, Klinikum Weiden, Weiden, Germany.
Email: [email protected]
Search for more papers by this authorJörg J. Vehreschild
Department for Internal Medicine, German Centre for Infection Research, University Hospital of Cologne, Partner Site Bonn-Cologne, University of Cologne, Köln, Germany
Search for more papers by this authorDieter Buchheidt
Department of Internal Medicine-Hematology and Oncology, Mannheim University Hospital, Heidelberg University, Mannheim, Germany
Search for more papers by this authorCorresponding Author
Werner J. Heinz
Klinikum Weiden, Weiden, Würzburg university medical center, Würzburg, Germany
Correspondence
Werner J. Heinz, Klinikum Weiden, Weiden, Germany.
Email: [email protected]
Search for more papers by this authorJörg J. Vehreschild
Department for Internal Medicine, German Centre for Infection Research, University Hospital of Cologne, Partner Site Bonn-Cologne, University of Cologne, Köln, Germany
Search for more papers by this authorDieter Buchheidt
Department of Internal Medicine-Hematology and Oncology, Mannheim University Hospital, Heidelberg University, Mannheim, Germany
Search for more papers by this authorSummary
In immunocompromised patients with acute leukaemia as well as in allogeneic hematopoietic stem cell transplant patients, pulmonary lesions are commonly seen. Existing guidelines provide useful algorithms for diagnostic procedures and treatment options, but they do not give recommendations on how to evaluate early success or failure and if or when it is best to change therapy. Here, we review the diagnostic techniques currently used in association with clinical findings and propose an approach using a combination of computer tomography, clinical and all available biomarkers and inflammation parameters, especially those positive at baseline, to assess early response in invasive pulmonary aspergillosis. Computed tomography scans should be carried out at regular intervals during early and long-term follow-up. Imaging on day seven, or even earlier in clinically unstable patients, combined with an additional testing of biomarkers and inflammatory markers in between, is needed for a reliable assessment at day 14. If no improvement is seen after 2 weeks of therapy or the clinical condition is deteriorating, a change of antifungal therapy should be considered. Alleged breakthrough infections or treatment failure should undergo early diagnostic workup, including tissue biopsies when possible, to retrieve fungal cultures for resistance testing.
REFERENCES
- 1Atalla A, Garnica M, Maiolino A, Nucci M. Risk factors for invasive mold diseases in allogeneic hematopoietic cell transplant recipients. Transpl Infect Dis. 2015; 17: 7-13.
- 2Kontoyiannis DP, Marr KA, Park BJ, et al. Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001–2006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database. Clin Infect Dis. 2010; 50: 1091-1100.
- 3Nivoix Y, Velten M, Letscher-Bru V, et al. Factors associated with overall and attributable mortality in invasive aspergillosis. Clin Infect Dis. 2008; 47: 1176-1184.
- 4Ruhnke M, Groll AH, Mayser P, et al. Estimated burden of fungal infections in Germany. Mycoses. 2015; 58(Suppl 5): 22-28.
- 5 Fungal disease frequency. https://www.gaffi.org/why/fungal-disease-frequency/. Accessed March 20, 2018.
- 6Mellinghoff SC, Panse J, Alakel N, et al. Primary prophylaxis of invasive fungal infections in patients with haematological malignancies: 2017 update of the recommendations of the infectious diseases working party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO). Ann Hematol. 2018; 97: 197-207.
- 7Chellapandian D, Lehrnbecher T, Phillips B, et al. Bronchoalveolar lavage and lung biopsy in patients with cancer and hematopoietic stem-cell transplantation recipients: a systematic review and meta-analysis. J Clin Oncol. 2015; 33: 501-509.
- 8Patterson TF, Thompson 3rd GR, Denning DW, et al. Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis. 2016; 63: e1-e60.
- 9Tissot F, Agrawal S, Pagano L, et al. ECIL-6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormycosis in leukemia and hematopoietic stem cell transplant patients. Haematologica. 2017; 102: 433-444.
- 10Ullmann AJ, Aguado JM, Arikan-Akdagli S, et al. Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline. Clin Microbiol Infect. 2018; 24(Suppl 1): e1-e38.
- 11Bassetti M, Bouza E. Invasive mould infections in the ICU setting: complexities and solutions. J Antimicrob Chemother. 2017; 72: i39-i47.
- 12Bassetti M, Righi E, De Pascale G, et al. How to manage aspergillosis in non-neutropenic intensive care unit patients. Crit Care. 2014; 18: 458.
- 13Maschmeyer G, Carratala J, Buchheidt D, et al. Diagnosis and antimicrobial therapy of lung infiltrates in febrile neutropenic patients (allogeneic SCT excluded): updated guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO). Ann Oncol. 2015; 26: 21-33.
- 14Segal BH, Herbrecht R, Stevens DA, et al. Defining responses to therapy and study outcomes in clinical trials of invasive fungal diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer consensus criteria. Clin Infect Dis. 2008; 47: 674-683.
- 15Nucci M, Perfect JR. When primary antifungal therapy fails. Clin Infect Dis. 2008; 46: 1426-1433.
- 16Ruping MJ, Vehreschild JJ, Groll A, et al. Current issues in the clinical management of invasive aspergillosis–the AGIHO, DMykG, OGMM and PEG web-based survey and expert consensus conference 2009. Mycoses. 2011; 54: e557-e568.
- 17Brodöfel H, Vogel M, Hebart H, et al. Long-term CT follow-up in 40 non-HIV immunocompromised patients with invasive pulmonary aspergillosis: kinetics of CT morphology and correlation with clinical findings and outcome. Am J Roentgenol. 2006; 187: 404-413.
- 18Kubo T, Ohno Y, Takenaka D, et al. Standard-dose vs. low-dose CT protocols in the evaluation of localized lung lesions: capability for lesion characterization—iLEAD study. Eur J Radiol Open 2016; 3: 67-73.
- 19Prasad A, Agarwal K, Deepak D, Atwal SS. Pulmonary aspergillosis: what ct can offer before it is too late!. J Clin Diagn Res 2016; 10: TE01-TE05.
- 20Georgiadou SP, Sipsas NV, Marom EM, Kontoyiannis DP. The diagnostic value of halo and reversed halo signs for invasive mold infections in compromised hosts. Clin Infect Dis. 2011; 52: 1144-1155.
- 21Caillot D, Couaillier JF, Bernard A, et al. Increasing volume and changing characteristics of invasive pulmonary aspergillosis on sequential thoracic computed tomography scans in patients with neutropenia. J Clin Oncol. 2001; 19: 253-259.
- 22Caillot D, Latrabe V, Thiebaut A, et al. Computer tomography in pulmonary invasive aspergillosis in hematological patients with neutropenia: an useful tool for diagnosis and assessment of outcome in clinical trials. Eur J Radiol. 2010; 74: e172-e175.
- 23Vehreschild JJ, Heussel CP, Groll AH, et al. Serial assessment of pulmonary lesion volume by computed tomography allows survival prediction in invasive pulmonary aspergillosis. Eur Radiol. 2017; 27: 3275-3282.
- 24Stanzani M, Battista G, Sassi C, et al. Computed tomographic pulmonary angiography for diagnosis of invasive mold diseases in patients with hematological malignancies. Clin Infect Dis. 2012; 54: 610-616.
- 25Stanzani M, Sassi C, Lewis RE, et al. High resolution computed tomography angiography improves the radiographic diagnosis of invasive mold disease in patients with hematological malignancies. Clin Infect Dis. 2015; 60: 1603-1610.
- 26Henzler C, Henzler T, Buchheidt D, et al. Diagnostic performance of contrast enhanced pulmonary computed tomography angiography for the detection of angioinvasive pulmonary aspergillosis in immunocompromised patients. Sci Rep. 2017; 7: 4483.
- 27Gafter-Gvili A, Paul M, Bernstine H, et al. The role of 18F-FDG PET/CT for the diagnosis of infections in patients with hematological malignancies and persistent febrile neutropenia. Leuk Res. 2013; 37: 1057-1062.
- 28Seban RD, Bonardel G, Guernou M, Lussato D, Queneau M. The use of FDG PET-CT imaging for the assessment of early antifungal treatment response in disseminated fusariosis. Clin Nucl Med. 2017; 42: 569-570.
- 29Vos FJ, Donnelly JP, Oyen WJ, Kullberg BJ, Bleeker-Rovers CP, Blijlevens NM. 18F-FDG PET/CT for diagnosing infectious complications in patients with severe neutropenia after intensive chemotherapy for haematological malignancy or stem cell transplantation. Eur J Nucl Med Mol Imaging. 2012; 39: 120-128.
- 30Rolle AM, Hasenberg M, Thornton CR, et al. ImmunoPET/MR imaging allows specific detection of Aspergillus fumigatus lung infection in vivo. Proc Natl Acad Sci U S A. 2016; 113: E1026-E1033.
- 31Lim C, Seo JB, Park SY, et al. Analysis of initial and follow-up CT findings in patients with invasive pulmonary aspergillosis after solid organ transplantation. Clin Radiol. 2012; 67: 1179-1186.
- 32Lim MC, Tan CH, Cai J, Zheng J, Kow AWC. CT volumetry of the liver: where does it stand in clinical practice? Clin Radiol. 2014; 69: 887-895.
- 33Buchheidt D, Reinwald M, Hoenigl M, Hofmann W-K, Spiess B, Boch T. The evolving landscape of new diagnostic tests for invasive aspergillosis in hematology patients: strengths and weaknesses. Curr Opin Infect Dis. 2017; 30: 539-544.
- 34Jaijakul S, Vazquez JA, Swanson RN, Ostrosky-Zeichner L. (1,3)-beta-D-glucan as a prognostic marker of treatment response in invasive candidiasis. Clin Infect Dis. 2012; 55: 521-526.
- 35Boch T, Spiess B, Cornely OA, et al. Diagnosis of invasive fungal infections in haematological patients by combined use of galactomannan, 1,3-beta-D-glucan, Aspergillus PCR, multifungal DNA-microarray, and Aspergillus azole resistance PCRs in blood and bronchoalveolar lavage samples: results of a prospective multicentre study. Clin Microbiol Infect. 2016; 22: 862-868.
- 36Eigl S, Prattes J, Reischies FM, et al. Galactomannan Testing and Aspergillus PCR in same-day bronchoalveolar lavage and blood samples obtained from patients with hematological malignancies at risk for invasive mould infection. Mycoses. 2015; 58: 157.
- 37Koo S, Bryar Julie M, Page John H, Baden Lindsey R, Marty Francisco M. Diagnostic performance of the (1->3) beta-D-Glucan assay for Invasive fungal disease. Clin Infect Dis. 2009; 49: 1650-1659.
- 38Marty FM, Koo S. Role of (1–>3)-beta-D-glucan in the diagnosis of invasive aspergillosis. Med Mycol. 2009; 47(Suppl 1): S233-S240.
- 39Pazos C, Ponton J, Del Palacio A. Contribution of (1->3)-beta-D-glucan chromogenic assay to diagnosis and therapeutic monitoring of invasive aspergillosis in neutropenic adult patients: a comparison with serial screening for circulating galactomannan. J Clin Microbiol. 2005; 43: 299-305.
- 40Zhou W, Li H, Zhang Y, et al. Diagnostic value of galactomannan antigen test in serum and bronchoalveolar lavage fluid samples from patients with nonneutropenic invasive pulmonary aspergillosis. J Clin Microbiol. 2017; 55: 2153-2161.
- 41Chai LY, Kullberg BJ, Earnest A, et al. Voriconazole or amphotericin B as primary therapy yields distinct early serum galactomannan trends related to outcomes in invasive aspergillosis. PLoS ONE. 2014; 9: e90176.
- 42Koo S, Bryar JM, Baden LR, Marty FM. Prognostic features of galactomannan antigenemia in galactomannan-positive invasive aspergillosis. J Clin Microbiol. 2010; 48: 1255-1260.
- 43Fisher CE, Stevens AM, Leisenring W, Pergam SA, Boeckh M, Hohl TM. The serum galactomannan index predicts mortality in hematopoietic stem cell transplant recipients with invasive aspergillosis. Clin Infect Dis. 2013; 57: 1001-1004.
- 44Woods G, Miceli MH, Grazziutti ML, Zhao W, Barlogie B, Anaissie E. Serum Aspergillus galactomannan antigen values strongly correlate with outcome of invasive aspergillosis: a study of 56 patients with hematologic cancer. Cancer. 2007; 110: 830-834.
- 45Boutboul F, Alberti C, Leblanc T, et al. Invasive aspergillosis in allogeneic stem cell transplant recipients: increasing antigenemia is associated with progressive disease. Clin Infect Dis. 2002; 34: 939-943.
- 46Chai LY, Kullberg BJ, Johnson EM, et al. Early serum galactomannan trend as a predictor of outcome of invasive aspergillosis. J Clin Microbiol. 2012; 50: 2330-2336.
- 47Miceli MH, Grazziutti ML, Woods G, et al. Strong correlation between serum aspergillus galactomannan index and outcome of aspergillosis in patients with hematological cancer: clinical and research implications. Clin Infect Dis. 2008; 46: 1412-1422.
- 48Bergeron A, Porcher R, Menotti J, et al. Prospective evaluation of clinical and biological markers to predict the outcome of invasive pulmonary aspergillosis in hematological patients. J Clin Microbiol. 2012; 50: 823-830.
- 49Kovanda LL, Desai AV, Hope WW. Prognostic value of galactomannan: current evidence for monitoring response to antifungal therapy in patients with invasive aspergillosis. J Pharmacokinet Pharmacodyn. 2017; 44: 143-151.
- 50Neofytos D, Treadway S, Ostrander D, et al. Epidemiology, outcomes, and mortality predictors of invasive mold infections among transplant recipients: a 10-year, single-center experience. Transpl Infect Dis. 2013; 15: 233-242.
- 51Mercier T, Guldentops E, Lagrou K, Maertens J. Galactomannan, a surrogate marker for outcome in invasive aspergillosis: finally coming of age. Front Microbiol. 2018; 9: 661.
- 52Kovanda LL, Kolamunnage-Dona R, Neely M, Maertens J, Lee M, Hope WW. Pharmacodynamics of isavuconazole for invasive mold disease: role of galactomannan for real-time monitoring of therapeutic response. Clin Infect Dis. 2017; 64: 1557-1563.
- 53Buchheidt D, Reinwald M, Hofmann WK, Boch T, Spiess B. Evaluating the use of PCR for diagnosing invasive aspergillosis. Expert Rev Mol Diagn. 2017; 17: 603-610.
- 54Hummel M, Spiess B, Cornely OA, Dittmer M, Morz H, Buchheidt D. Aspergillus PCR testing: results from a prospective PCR study within the AmBiLoad trial. Eur J Haematol. 2010; 85: 164-169.
- 55Barnes RA, White PL, Morton CO, et al. Diagnosis of aspergillosis by PCR: clinical considerations and technical tips. Med Mycol. 2018; 56: 60-72.
- 56Imbert S, Gauthier L, Joly I, et al. Aspergillus PCR in serum for the diagnosis, follow-up and prognosis of invasive aspergillosis in neutropenic and nonneutropenic patients. Clin Microbiol Infect. 2016; 22(562): e1-e8.
- 57Thornton CR. Development of an immunochromatographic lateral-flow device for rapid serodiagnosis of invasive aspergillosis. Clin Vaccine Immunol. 2008; 15: 1095-1105.
- 58Hoenigl M, Koidl C, Duettmann W, et al. Bronchoalveolar lavage lateral-flow device test for invasive pulmonary aspergillosis diagnosis in haematological malignancy and solid organ transplant patients. J Infect. 2012; 65: 588-591.
- 59Johnson GL, Sarker SJ, Nannini F, et al. Aspergillus-specific lateral-flow device and real-time PCR testing of bronchoalveolar lavage fluid: a combination biomarker approach for clinical diagnosis of invasive pulmonary aspergillosis. J Clin Microbiol. 2015; 53: 2103-2108.
- 60Miceli MH, Goggins MI, Chander P, et al. Performance of lateral flow device and galactomannan for the detection of Aspergillus species in bronchoalveolar fluid of patients at risk for invasive pulmonary aspergillosis. Mycoses. 2015; 58: 368-374.
- 61Eigl S, Prattes J, Reinwald M, et al. Influence of mould-active antifungal treatment on the performance of the Aspergillus-specific bronchoalveolar lavage fluid lateral-flow device test. Int J Antimicrob Agents. 2015; 46: 401-405.
- 62Cho HJ, Jang MS, Hong SD, Chung SK, Kim HY, Dhong HJ. Prognostic factors for survival in patients with acute invasive fungal rhinosinusitis. Am J Rhinol Allergy. 2015; 29: 48-53.
- 63Zhao Y, Nagasaki Y, Paderu P, et al. Applying host disease status biomarkers to therapeutic response monitoring in invasive aspergillosis patients. Med Mycol. 2019; 57: 38-44.
- 64Chai L, Netea MG, Teerenstra S, et al. Early proinflammatory cytokines and C-reactive protein trends as predictors of outcome in invasive aspergillosis. J Infect Dis. 2010; 202: 1454-1462.
- 65Roques M, Chretien ML, Favennec C, et al. Evolution of procalcitonin, C-reactive protein and fibrinogen levels in neutropenic leukaemia patients with invasive pulmonary aspergillosis or mucormycosis. Mycoses. 2016; 59: 383-390.
- 66Schuetz P, Wirz Y, Sager R, et al. Effect of procalcitonin-guided antibiotic treatment on mortality in acute respiratory infections: a patient level meta-analysis. Lancet Infect Dis. 2018; 18: 95-107.
- 67Krel M, Petraitis V, Petraitiene R, et al. Host biomarkers of invasive pulmonary aspergillosis to monitor therapeutic response. Antimicrob Agents Chemother. 2014; 58: 3373-3378.